Track topics on Twitter Track topics that are important to you
Auxogyn’s non-invasive Early Embryo Viability Assessment Test (Eeva) may improve in vitro fertilization (IVF) outcomes by providing IVF clinics and patients with objective information on embryo viability. Eeva’s proprietary software automatically analyzes embryo development against scientifically and clinically validated cell-division timing parameters. With Eeva’s quantitative data on each embryo’s development potential, IVF clinics can optimize the treatment path for their patients undergoing IVF procedures.
When used with traditional embryo assessment techniques, Eeva may give IVF clinics and their patients the potential to improve clinical success. With greater opportunity for success, it may be possible to reduce multiple births by enabling single embryo transfer for a large number of patients.
CAUTION-Investigational Device. Limited by Federal (United States) law to investigational use.
MENLO PARK, Calif., July 3, 2013 /PRNewswire/ -- Auxogyn, Inc., a company focused on revolutionizing the field of reproductive medicine by providing novel scientific and clinically validated solutions...
The purpose of this clinical trial is to collect imaging data on embryos followed to blastocyst stage (Day 5-6) for ongoing development and validation of the Eeva System.
The purpose of this clinical investigation is to gather data to evaluate the impact of using Eeva with traditional morphology grading on implantation rates.
The purpose of this study is to record and evaluate the use of traditional morphology grading combined with Eeva in the treatment of in vitro fertilization.